IDEXX LABORATORIES INC (IX1.DE) Stock Fundamental Analysis
FRA:IX1 • US45168D1046
539.8 EUR
-0.8 (-0.15%)
Last: Feb 12, 2026, 07:00 PM
IX1 gets a fundamental rating of 6 out of 10. The analysis compared the fundamentals against 67 industry peers in the Health Care Equipment & Supplies industry. Both the health and profitability get an excellent rating, making IX1 a very profitable company, without any liquidiy or solvency issues. While showing a medium growth rate, IX1 is valued expensive at the moment. With these ratings, IX1 could be worth investigating further for quality investing!.
1. Profitability
1.1 Basic Checks
- In the past year IX1 was profitable.
- In the past year IX1 had a positive cash flow from operations.
- In the past 5 years IX1 has always been profitable.
- IX1 had a positive operating cash flow in each of the past 5 years.
1.2 Ratios
- IX1's Return On Assets of 30.34% is amongst the best of the industry. IX1 outperforms 100.00% of its industry peers.
- IX1 has a Return On Equity of 65.81%. This is amongst the best in the industry. IX1 outperforms 100.00% of its industry peers.
- The Return On Invested Capital of IX1 (40.35%) is better than 100.00% of its industry peers.
- Measured over the past 3 years, the Average Return On Invested Capital for IX1 is significantly above the industry average of 9.66%.
- The 3 year average ROIC (37.60%) for IX1 is below the current ROIC(40.35%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.35% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
1.3 Margins
- IX1's Profit Margin of 24.65% is amongst the best of the industry. IX1 outperforms 94.03% of its industry peers.
- In the last couple of years the Profit Margin of IX1 has grown nicely.
- IX1 has a better Operating Margin (31.34%) than 100.00% of its industry peers.
- IX1's Operating Margin has improved in the last couple of years.
- With a Gross Margin value of 61.72%, IX1 perfoms like the industry average, outperforming 58.21% of the companies in the same industry.
- IX1's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
2. Health
2.1 Basic Checks
- With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IX1 is creating value.
- IX1 has less shares outstanding than it did 1 year ago.
- The number of shares outstanding for IX1 has been reduced compared to 5 years ago.
- The debt/assets ratio for IX1 has been reduced compared to a year ago.
2.2 Solvency
- IX1 has an Altman-Z score of 21.77. This indicates that IX1 is financially healthy and has little risk of bankruptcy at the moment.
- With an excellent Altman-Z score value of 21.77, IX1 belongs to the best of the industry, outperforming 98.51% of the companies in the same industry.
- IX1 has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
- IX1's Debt to FCF ratio of 1.04 is amongst the best of the industry. IX1 outperforms 86.57% of its industry peers.
- A Debt/Equity ratio of 0.53 indicates that IX1 is somewhat dependend on debt financing.
- Looking at the Debt to Equity ratio, with a value of 0.53, IX1 is in line with its industry, outperforming 41.79% of the companies in the same industry.
- Although IX1 does not score too well on debt/equity it has very limited outstanding debt, which is well covered by the FCF. We will not put too much weight on the debt/equity number as it may be because of low equity, which could be a consequence of a share buyback program for instance. This needs to be investigated.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 21.77 |
ROIC/WACC4.03
WACC10.01%
2.3 Liquidity
- IX1 has a Current Ratio of 1.18. This is a normal value and indicates that IX1 is financially healthy and should not expect problems in meeting its short term obligations.
- IX1's Current ratio of 1.18 is on the low side compared to the rest of the industry. IX1 is outperformed by 70.15% of its industry peers.
- IX1 has a Quick Ratio of 1.18. This is a bad value and indicates that IX1 is not financially healthy enough and could expect problems in meeting its short term obligations.
- Looking at the Quick ratio, with a value of 0.87, IX1 is doing worse than 67.16% of the companies in the same industry.
- The current and quick ratio evaluation for IX1 is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
- IX1 shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 16.18%, which is quite good.
- The Earnings Per Share has been growing by 14.26% on average over the past years. This is quite good.
- IX1 shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 10.42%.
- The Revenue has been growing by 9.72% on average over the past years. This is quite good.
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
3.2 Future
- The Earnings Per Share is expected to grow by 13.75% on average over the next years. This is quite good.
- IX1 is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.46% yearly.
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y9.46%
3.3 Evolution
- When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
- The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
- A Price/Earnings ratio of 48.54 indicates a quite expensive valuation of IX1.
- 64.18% of the companies in the same industry are cheaper than IX1, based on the Price/Earnings ratio.
- When comparing the Price/Earnings ratio of IX1 to the average of the S&P500 Index (27.09), we can say IX1 is valued expensively.
- IX1 is valuated quite expensively with a Price/Forward Earnings ratio of 42.82.
- Based on the Price/Forward Earnings ratio, IX1 is valued a bit more expensive than the industry average as 71.64% of the companies are valued more cheaply.
- The average S&P500 Price/Forward Earnings ratio is at 27.98. IX1 is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.54 | ||
| Fwd PE | 42.82 |
4.2 Price Multiples
- Based on the Enterprise Value to EBITDA ratio, IX1 is valued a bit more expensive than 68.66% of the companies in the same industry.
- Compared to the rest of the industry, the Price/Free Cash Flow ratio of IX1 is on the same level as its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 53.88 | ||
| EV/EBITDA | 35.25 |
4.3 Compensation for Growth
- The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
- IX1 has an outstanding profitability rating, which may justify a higher PE ratio.
- A more expensive valuation may be justified as IX1's earnings are expected to grow with 13.30% in the coming years.
PEG (NY)3.63
PEG (5Y)3.4
EPS Next 2Y13.1%
EPS Next 3Y13.3%
5. Dividend
5.1 Amount
- IX1 does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
FRA:IX1 (2/12/2026, 7:00:00 PM)
539.8
-0.8 (-0.15%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-02 2026-02-02/bmo
Earnings (Next)04-29 2026-04-29/bmo
Inst Owners94.94%
Inst Owner ChangeN/A
Ins Owners0.21%
Ins Owner ChangeN/A
Market Cap43.10B
Revenue(TTM)4.30B
Net Income(TTM)1.03B
Analysts80.91
Price Target692.16 (28.23%)
Short Float %N/A
Short RatioN/A
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)0.74%
PT rev (3m)38%
EPS NQ rev (1m)-0.03%
EPS NQ rev (3m)8.57%
EPS NY rev (1m)0.19%
EPS NY rev (3m)7.67%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)7.15%
Revenue NY rev (1m)0.19%
Revenue NY rev (3m)3.88%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 48.54 | ||
| Fwd PE | 42.82 | ||
| P/S | 12.16 | ||
| P/FCF | 53.88 | ||
| P/OCF | 46.56 | ||
| P/B | 32.45 | ||
| P/tB | 49.05 | ||
| EV/EBITDA | 35.25 |
EPS(TTM)11.12
EY2.06%
EPS(NY)12.61
Fwd EY2.34%
FCF(TTM)10.02
FCFY1.86%
OCF(TTM)11.59
OCFY2.15%
SpS44.41
BVpS16.64
TBVpS11
PEG (NY)3.63
PEG (5Y)3.4
Graham Number64.51
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.35% | ||
| ROICexc | 43.87% | ||
| ROICexgc | 56.38% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)28.17%
ROA(5y)27.96%
ROE(3y)59.52%
ROE(5y)79.62%
ROIC(3y)37.6%
ROIC(5y)38.02%
ROICexc(3y)42.72%
ROICexc(5y)42.26%
ROICexgc(3y)50.78%
ROICexgc(5y)53.04%
ROCE(3y)53.41%
ROCE(5y)55.15%
ROICexgc growth 3Y-1.85%
ROICexgc growth 5Y-3.56%
ROICexc growth 3Y7.2%
ROICexc growth 5Y1.43%
OM growth 3Y5.66%
OM growth 5Y4.24%
PM growth 3Y6.87%
PM growth 5Y2.75%
GM growth 3Y1.26%
GM growth 5Y1.26%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 21.77 |
F-Score8
WACC10.01%
ROIC/WACC4.03
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)3.3%
Cap/Sales(5y)3.67%
Profit Quality(3y)93.71%
Profit Quality(5y)84.62%
High Growth Momentum
Growth
EPS 1Y (TTM)16.18%
EPS 3Y17.63%
EPS 5Y14.26%
EPS Q2Q%17.56%
EPS Next Y13.36%
EPS Next 2Y13.1%
EPS Next 3Y13.3%
EPS Next 5Y13.75%
Revenue 1Y (TTM)10.42%
Revenue growth 3Y8.52%
Revenue growth 5Y9.72%
Sales Q2Q%14.28%
Revenue Next Year8.92%
Revenue Next 2Y8.91%
Revenue Next 3Y9.16%
Revenue Next 5Y9.46%
EBIT growth 1Y17.46%
EBIT growth 3Y14.66%
EBIT growth 5Y14.37%
EBIT Next Year22.21%
EBIT Next 3Y14.34%
EBIT Next 5Y15.18%
FCF growth 1Y18.62%
FCF growth 3Y40.13%
FCF growth 5Y14.37%
OCF growth 1Y18.68%
OCF growth 3Y29.59%
OCF growth 5Y12.77%
IDEXX LABORATORIES INC / IX1.DE FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IX1.DE) stock?
ChartMill assigns a fundamental rating of 6 / 10 to IX1.DE.
What is the valuation status of IDEXX LABORATORIES INC (IX1.DE) stock?
ChartMill assigns a valuation rating of 2 / 10 to IDEXX LABORATORIES INC (IX1.DE). This can be considered as Overvalued.
What is the profitability of IX1 stock?
IDEXX LABORATORIES INC (IX1.DE) has a profitability rating of 9 / 10.
What is the financial health of IDEXX LABORATORIES INC (IX1.DE) stock?
The financial health rating of IDEXX LABORATORIES INC (IX1.DE) is 8 / 10.